Bryant Furlow

Contributing Writer https://www.cancertherapyadvisor.com

Bryant Furlow is a contract medical journalist for the Haymarket Medical Network. He holds a bachelor of science in biology (summa cum laude) from the University of New Mexico. He covers radiation oncology, immunotherapy, tumor biology, clinical research, and health care policy. Prior to becoming a contributor to Haymarket Media in 2010, Bryant was a newspaper reporter in New Mexico, where he won awards for public health and investigative journalism. He also reports for The Lancet Oncology news desk.

All articles by Bryant Furlow

Trastuzumab emtansine reduces the risk of recurrence by 50% in some HER2-positive breast cancers following neoadjuvant chemotherapy.

ESMO 2019

Abemaciclib Plus Fulvestrant Improved Survival in Patients with HR+, HER2- Advanced Breast Cancer

Bryant Furlow

September 30, 2019

Results of MONARCH-2 showed a statistically significant and clinically meaningful improvement in overall survival with abemaciclib plus fulvestrant.

ESMO 2019

Pembrolizumab Does Not Prolong Survival Compared With Chemotherapy in Metastatic TNBC

Bryant Furlow

September 29, 2019

Pembrolizumab monotherapy does not improve overall survival (OS) compared with single-agent chemotherapy among women with metastatic triple negative breast cancer (mTNBC).

ESMO 2019

Adjuvant Sorafenib Does Not Improve Survival in Renal Cell Carcinoma

Bryant Furlow

September 29, 2019

Active surveillance remains the standard of care for patients at intermediate or high risk of recurrence following nephrectomy.

Findings from the SPARTAN trial show that HRQoL is not diminished by adding apalutamide to androgen

ESMO 2019

First-Line Combination Immunotherapy Deemed Superior to Chemotherapy in Advanced Lung Cancer

Bryant Furlow

September 29, 2019

“In my opinion, these data are practice changing,” said lead study author Solange Peters.

Afatinib may demonstrate clinical activity in patients with EGFR mutation-positive non-small cell lu

ESMO 2019

Biomarkers May Predict Immune Checkpoint Blockade-Related Hyperprogression in Lung Cancer

Bryant Furlow

September 28, 2019

Nearly 11% of patients in the study who underwent immune checkpoint inhibition for NSCLC experienced HPD.

An Italian trial reported fewer deaths with annual or biennial low-dose CT lung screening—and an active surveillance approach reduced overdiagnosis.

ESMO 2019

Real-World Survival Rates Reported for Nivolumab in Previously Treated NSCLC

Bryant Furlow

September 28, 2019

Nivolumab monotherapy for advanced NSCLC was associated with lower overall survival rates in real-world settings than those seen in clinical trial settings.

Recent and upcoming case reports suggest possible cases of gluteal and other implant-associated ALCLs, raising questions about the cancer risk across all types of implants.

Lymphoma

Implant-Associated Cancers: A Look Beyond BIA-ALCL

Bryant Furlow

September 16, 2019

Recent and upcoming case reports suggest possible cases of gluteal and other implant-associated ALCLs, raising questions about the cancer risk across all types of implants.

Organoids created from tumor samples have been revolutionizing laboratory research, but they also may begin helping oncologists decide on treatment regimens for patients.

Lung Cancer

Recent Advances Offer Paths Forward for Developing Predictive Biomarkers in Cancer Immunotherapy

Bryant Furlow

September 4, 2019

Recent advances in predictive biomarker development clarify how best to determine PD-L1 expression in tumor cells.

Lung Cancer

Upfront Next-Generation Sequencing for Lung Cancer: Can It Save Time and Money?

Bryant Furlow

July 3, 2019

Upfront NGS saves time and money compared with the sequential use of individual gene tests for patients with metastatic lung cancer, according to study authors.

Renal Cell Carcinoma

IL-2 and Metastatic Renal Cell Carcinoma

Bryant Furlow

May 31, 2019

Despite a challenging toxicity profile, high dose interleukin-2 (HD IL-2), one of the earliest-approved immunotherapies for metastatic renal cell carcinoma still has a role in treating selected patients, a new registry analysis shows.

Next post in Renal Cell Carcinoma